SORL1 and breast cancer: Immunohistochemical staining of SORLA in a breast cancer tissue microarray (TMA) revealed that a substantial proportion (38%) of HER2-amplified breast cancers express moderate to high SORLA, indicating that HER2-amplified breast cancers fall into two subtypes with respect to SORLA positivity (Fig. 5a).